• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, August 21, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

GW cancer researchers investigate nanoimmunotherapies for cancer

Bioengineer by Bioengineer
January 28, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Rohan Fernandes, PhD, is leading a team in investigating the efficacy of a nanoimmunotherapy ensemble in treating cancer

WASHINGTON (Jan. 28, 2018) — A team from the George Washington University (GW) Cancer Center has engineered a nanoimmunotherapy that combines the advantages of nanotechnology and immunotherapy to treat cancer. The goal of this nanoimmunotherapy combination is to increase the potency of immune checkpoint inhibitors, a class of immunotherapy that elicits dramatic benefits in only a modest subset of cancer patients, to a significantly larger proportion of patients

Rohan Fernandes, PhD, assistant professor of medicine at the GW School of Medicine and Health Sciences, received more than $1.6 million from the National Institutes of Health for the study. The grant is a R37 award, which is a MERIT — Method to Extend Research in Time — Award for early stage investigators to give them the flexibility and opportunity for creativity and innovation, as well as, additional time to successfully launch their careers.

The researchers will work with Prussian blue nanoparticles (PBNPs) coated with immunological signals, used in combination with checkpoint inhibitors.

Prussian blue is a mixed valence, inorganic nanoparticle that has been historically used as a dark blue pigment. It exhibits unique electrical, optical, and magnetic properties, which make Prussian blue a candidate for several biological, medicinal, and other applications, including photothermal therapy.

“We believe that the ensemble approach to targeting tumor cells and neighboring immune cells using PBNPs hold the key in converting non-responsive, immunologically ‘cold’ tumors into responsive ‘hot’ tumors,” Fernandes said.

After elucidating the effects of PBNPs used for photothermal therapy on the tumor and adjacent immune cells, Fernandes will test the efficacy of the ensemble nanoimmunotherapy on tumor eradication and relapse prevention, and will evaluate the success of nanoimmunotherapy in treating disseminated cancer.

“If we are successful, this study will provide an impetus for clinical translation of our nanoimmunotherapy,” said Fernandes. “We could then achieve our goal of extending lasting benefits to a larger population of cancer patients.”

The team’s nanoimmunotherapy was engineered in collaboration with colleagues at the University of Maryland and Children’s National Health System.

The study, titled “Engineered Ensemble Nanoimmunotherapies for Cancer,” will be funded through November 2022.

###

Media Contact
Ashley Rizzardo
[email protected]
202-994-8679
https://smhs.gwu.edu/news/gw-cancer-researchers-investigate-nanoimmunotherapies-cancer

Tags: cancerCollaborationGrants/FundingMedicine/HealthNanotechnology/MicromachinesResearchers/Scientists/Awards
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Beijing Tiantan Hospital Researchers Develop Innovative One-Stage Hybrid Surgery for Brain and Spine Tumors

August 21, 2025
New Study Charts DNA Damage Timeline in Multiple Myeloma Development

New Study Charts DNA Damage Timeline in Multiple Myeloma Development

August 21, 2025

New Study Uncovers Key Genes That Suppress Blood Cancer Progression

August 21, 2025

Reformulated Cancer Drug Enhances Tumor Targeting and Strengthens Combination Therapy Outcomes

August 21, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Decoding mTORC1’s Dynamic Amino Acid Control

Maternal and Infant Gut Microbiota Linked to Infant Respiratory Infections

Wearable Devices Improve Parkinson’s Medication Adjustments: Trial

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.